Cargando…

Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data

INTRODUCTION: Although mefloquine use is known to be associated with a risk of severe neuropsychiatric adverse reactions that are often preceded by prodromal symptoms, specific combinations of neurologic or psychiatric reactions associated with mefloquine use are not well described in the literature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nevin, Remington L., Leoutsakos, Jeannie-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318335/ https://www.ncbi.nlm.nih.gov/pubmed/28063022 http://dx.doi.org/10.1007/s40268-016-0167-3

Ejemplares similares

A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions
por: Nevin, Remington L.
Publicado: (2017)

Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada
por: Nevin, Remington L., et al.
Publicado: (2016)

Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria
por: Naing, Cho, et al.
Publicado: (2012)

Misclassification and Bias in Military Studies of Mefloquine
por: Lee Nevin, Remington
Publicado: (2017)

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions
por: Okada, Motohiro, et al.
Publicado: (2020)

Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes
por: Haaksma, Miriam L., et al.
Publicado: (2018)

Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019)

Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis
por: Nevin, Remington L
Publicado: (2009)

A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class
por: Hoffman, Keith B., et al.
Publicado: (2012)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Exploring adverse drug events at the class level
por: Winnenburg, Rainer, et al.
Publicado: (2015)

Adverse childhood experiences and adult inflammation: Single adversity, cumulative risk and latent class approaches
por: Lacey, Rebecca E., et al.
Publicado: (2020)

Rational Risk-Benefit Decision-Making in the Setting of Military Mefloquine Policy
por: Nevin, Remington L.
Publicado: (2015)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Discrimination and Adverse Perinatal Health Outcomes: A Latent Class Analysis
por: Doherty, Emily A., et al.
Publicado: (2023)

Bias and Confounding in Studies of Chronic Mental Health Effects from Mefloquine Exposure
por: Nevin, Remington Lee
Publicado: (2019)

Severe Neuropsychiatric Reaction in a Deployed Military Member after Prophylactic Mefloquine
por: Peterson, Alan L., et al.
Publicado: (2011)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine()
por: Nevin, Remington L.
Publicado: (2014)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

1977. Comparing Acute Kidney Injury Risk among Antibiotic Classes: A Study of the FDA Adverse Event Reporting System (FAERS)
por: Patek, Taylor M, et al.
Publicado: (2019)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: a case report
por: Jain, Manish, et al.
Publicado: (2016)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan
por: Nevin, Remington L, et al.
Publicado: (2008)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

A large-scale survey of adverse events experienced in yoga classes
por: Matsushita, Tomoko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_brh5e86j4d3lmkoll7hfmeg98m